Rheumatic Heart Disease Market
Global Rheumatic heart disease Market Size, Share & Trends Analysis Report by Treatment (Antibiotics Medication, Anti-Convulsant Medication, Anti-Inflammatory Treatment, and Surgical Treatment), By Type (Valve, Myocarditis, and Pericarditis), By Diagnostics Tests (Electrocardiogram, Echocardiogram, Blood Test, and Imaging), By End-User (Hospitals and Clinics, Diagnostic Centres, and Research centers) Forecast 2021-2027
The global rheumatic heart disease market is anticipated to grow at a CAGR of 6.0% during the forecast period. Rheumatic fever is most common in children aged 5 to 15, however, it can also affect adults. Rheumatic fever can cause long-term damage to the heart and heart valves in some people. Rheumatic heart disease is an inflammatory condition that begins with a typical strep throat infection, a fever, and several joint pains. Furthermore, failing to treat these symptoms affects the heart, causing damage to the heart valves and eventually leading to rheumatic heart disease (RHD). The key bacterium that causes rheumatic fever is Streptococcus pyogenes. Various hazardous materials from the atmosphere, such as water, food, air, toxic gases, smoke, and pollution, brought these infectious agents into contact with the human body.
One of the major factors driving this market's growth is rising environmental pollution, which leads to a higher prevalence of viral and fungal infection. Furthermore, the government's increased healthcare spending to combat the growing incidence of cardiovascular disease is another driving factor for the industry. The high cost of medical treatment and the lack of healthcare facilities in emerging economies could limit the market's growth. The leading market players' continuous improvement in Rheumatic heart disease drug and biotechnology growth has created new opportunities in the Rheumatic heart disease market.
Impact of COVID-19 Pandemic on Global Rheumatic Heart Disease Market
The global rheumatic heart disease market is hit by the COVID-19 pandemic since December 2019. Healthcare services were particularly stressed, as they had to respond to the rapid increase in demand by rising response capability and prioritizing assistance to COVID-19 patients. Along with the introduction of travel restrictions and social exclusion interventions, this was critical in reducing direct mortality. The outbreak of COVID-19 has disrupted the supply of raw materials and products, and manufacturing units across the globe. As doctors frontline warriors fighting against COVID-19, all other treatment procedures were postponed except emergency cases.
The COVID-19 pandemic shows severe symptoms in people, who are already suffering from chronic disease. Patients with rheumatic disorders are at risk of getting their follow-up compromised, which may lead to further problems as a result of untreated illness and undetected serious side effects from ongoing procedures. To deal with this and respond to patient needs, rheumatology departments must have adjusted their organic structure rapidly to the changing situation. The market will witness “V” shape recovery in near future owing to the restart of key industries in major economies.
Segmental Outlook
The global rheumatic heart disease market is segmented based on treatment, type, diagnostics tests, and end-users. Based on the treatment, the market is segmented into antibiotics medication, anti-convulsant medication, anti-inflammatory treatment, and surgical treatment. Based on type, the market is segmented into valve, myocarditis, and pericarditis. Besides, the valve is bifurcated into the aortic valve and mitral valve. Based on the diagnostics tests, the market is segmented into electrocardiogram, echocardiogram, blood test, and Imaging. Apart from this, by end-users, the market is segmented into hospitals and clinics, diagnostic centres, and research centres.
Global Rheumatic heart disease Market Share by Type, 2020 (%)
Valve Segment holds a significant share in the Global Rheumatic Heart Disease Market
Among type segment for rheumatic heart disease, the valve segment held the highest share in 2020 and is also anticipated to grow during the forecast period. The Valve segment is further bifurcated into the aortic valve and mitral valve. Among these, the mitral valve is projected to grow by 2027. This is growing due to rising key players' initiatives, expansion of geographical location, new product launches, technological advancements, among others. For instance, Abbott's leadership role in mitral repair will continue to expand, as the MitraClip product recently received reimbursement approval in Japan, bringing the total number of countries where MitraClip is used to over 50. Apart from it, With the launches by Abbott Laboratories in April 2020 of new heart devices such as Tendyne transcatheter mitral valve implantation system and TriClip transcatheter tricuspid valve repair system both had received CE Mark approvals and also expected to assist fill the gaps in treatment.
Regional Outlooks
The global rheumatic heart disease market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others), and the Rest of the World (the Middle East and Africa, and Latin America). The growing number of collaborations and partnerships by major pharmaceutical companies, to provide better healthcare facilities in Europe is the market driver in the European region.
Global Rheumatic heart disease Market Growth, by Region 2021-2027
Asia-Pacific is projected to have a considerable growth in the Global Rheumatic heart disease market
Asia-Pacific is anticipated to have a considerable growth in the global rheumatic heart disease market. In The rapidly developing healthcare infrastructure is the factor that is growing the market demand in the region. The presence of a large patient pool with unmet medical needs is one of the major factors contributing to this fastest growth of the region. Rheumatic heart disease can lead to heart valve injury, stroke, heart failure, and death if left untreated. Advanced disease treatment necessitates expensive surgery, which is not possible in many countries of the region is hindering the market growth.
Market Players Outlook
The key players of the global rheumatic heart disease market Abbott Laboratories, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer, Cook Group Inc., InterValve Medical Inc., Bristol Myers Squibb Co, among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in May 2020, Bristol Myers Squibb and MyoKardia, Inc. had announced a merger agreement under which Bristol Myers Squibb had acquired MyoKardia for $13.1 billion, or $225.0 per share in cash.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global rheumatic heart disease market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Rheumatic Heart DiseaseIndustry
• Recovery Scenario of Global Rheumatic Heart DiseaseIndustry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Rheumatic Heart Disease Market by Treatment
5.1.1. Antibiotics Medication
5.1.2. Anti-Convulsant Medication
5.1.3. Anti-Inflammatory Treatment
5.1.4. Surgical Treatment
5.2. Global Rheumatic Heart Disease Market by Type
5.2.1. Valve
5.2.1.1. Aortic Valve
5.2.1.2. Mitral Valve
5.2.2. Myocarditis
5.2.3. Pericarditis
5.3. Global Rheumatic Heart Disease Market by Diagnostics Test
5.3.1. Electrocardiogram
5.3.2. Echocardiogram
5.3.3. Blood Test
5.3.4. Imaging
5.4. Global Rheumatic Heart Disease Market by End-User
5.4.1. Hospitals and Clinics
5.4.2. Diagnostic Centres
5.4.3. Research Centers
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Abbott Laboratories
7.2. Bayer AG
7.3. BIOTRONIK, Inc.
7.4. Boston Scientific Corp.
7.5. Bristol-Myers Squibb Co.
7.6. Becton, Dickinson and Co.
7.7. Cardinal Health, Inc.
7.8. Cook Group Inc
7.9. F. Hoffmann-La Roche Ltd.
7.10. General Electric Co.
7.11. InterValve Medical Inc.
7.12. Novartis AG
7.13. On-X Life Technologies, Inc.
7.14. Osypka Medical GmbH
7.15. Otsuka Holdings Co. Ltd.
7.16. PerkinElmer Inc.
7.17. Pfizer Inc.
7.18. Reckitt Benckiser Group PLC
7.19. Siemens Healthcare GmbH
7.20. Toray Industries, Inc.
1. GLOBAL RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
2. GLOBAL RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
3. GLOBAL ANTIBIOTICS MEDICATION FOR RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
4. GLOBAL ANTI-CONVULSANT MEDICATION FOR RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
5. GLOBAL ANTI-INFLAMMATORY TREATMENT FOR RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
6. GLOBAL SURGICAL TREATMENT FOR RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
7. GLOBAL RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
8. GLOBAL VALVE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
9. GLOBAL VALVE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
10. GLOBAL MYOCARDITIS RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
11. GLOBAL PERICARDITIS RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
12. GLOBAL RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS TEST, 2020-2027 ($ MILLION)
13. GLOBAL ELECTROCARDIOGRAM IN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
14. GLOBAL ECHOCARDIOGRAM IN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
15. GLOBAL BLOOD TEST IN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
16. GLOBAL IMAGING IN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
17. GLOBAL RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
18. GLOBAL RHEUMATIC HEART DISEASE FOR HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
19. GLOBAL RHEUMATIC HEART DISEASE FOR DIAGNOSTIC CENTRES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
20. GLOBAL RHEUMATIC HEART DISEASE FOR RESEARCH CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
21. NORTH AMERICAN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
22. NORTH AMERICAN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
23. NORTH AMERICAN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
24. NORTH AMERICAN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS TESTS, 2020-2027 ($ MILLION)
25. NORTH AMERICAN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
26. EUROPEAN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
27. EUROPEAN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
28. EUROPEAN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
29. EUROPEAN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS TESTS, 2020-2027 ($ MILLION)
30. EUROPEAN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
31. ASIA-PACIFIC RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
32. ASIA-PACIFIC RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
33. ASIA-PACIFIC RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
34. ASIA-PACIFIC RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS TESTS, 2020-2027 ($ MILLION)
35. ASIA-PACIFIC RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
36. REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
37. REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
38. REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
39. REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS TESTS, 2020-2027 ($ MILLION)
40. REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL RHEUMATIC HEART DISEASE MARKET, 2020-2027 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL RHEUMATIC HEART DISEASE MARKET BY SEGMENT, 2020-2027 ($ MILLION)
3. RECOVERY OF GLOBAL RHEUMATIC HEART DISEASE MARKET, 2021-2027 (%)
4. GLOBAL RHEUMATIC HEART DISEASE MARKET SHARE BY TREATMENT, 2020 VS 2027 (%)
5. GLOBAL RHEUMATIC HEART DISEASE MARKET SHARE BY TYPE, 2020 VS 2027 (%)
6. GLOBAL RHEUMATIC HEART DISEASE MARKET SHARE BY DIAGNOSTICS TESTS, 2020 VS 2027 (%)
7. GLOBAL RHEUMATIC HEART DISEASE MARKET SHARE BY END-USER, 2020 VS 2027 (%)
8. GLOBAL RHEUMATIC HEART DISEASE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
9. GLOBAL ANTIBIOTICS MEDICATION FOR RHEUMATIC HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
10. GLOBAL ANTI-CONVULSANT MEDICATION FOR RHEUMATIC HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
11. GLOBAL ANTI-INFLAMMATORY TREATMENT FOR RHEUMATIC HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
12. GLOBAL SURGICAL TREATMENT FOR RHEUMATIC HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
13. GLOBAL VALVE RHEUMATIC HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
14. GLOBAL MYOCARDITIS RHEUMATIC HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
15. GLOBAL PERICARDITIS RHEUMATIC HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
16. GLOBAL ELECTROCARDIOGRAM IN RHEUMATIC HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
17. GLOBAL ECHOCARDIOGRAM IN RHEUMATIC HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
18. GLOBAL BLOOD TEST IN RHEUMATIC HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
19. GLOBAL IMAGING IN RHEUMATIC HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
20. GLOBAL RHEUMATIC HEART DISEASE FOR HOSPITALS AND CLINICS MARKET SHARE BY REGION, 2020 VS 2027(%)
21. GLOBAL RHEUMATIC HEART DISEASE FOR DIAGNOSTIC CENTRES MARKET SHARE BY REGION, 2020 VS 2027(%)
22. GLOBAL RHEUMATIC HEART DISEASE FOR RESEARCH CENTERS MARKET SHARE BY REGION, 2020 VS 2027(%)
23. US RHEUMATIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
24. CANADA RHEUMATIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
25. UK RHEUMATIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
26. FRANCE RHEUMATIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
27. GERMANY RHEUMATIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
28. ITALY RHEUMATIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
29. SPAIN RHEUMATIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
30. REST OF EUROPE RHEUMATIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
31. INDIA RHEUMATIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
32. CHINA RHEUMATIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
33. JAPAN RHEUMATIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
34. SOUTH KOREA RHEUMATIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
35. REST OF ASIA-PACIFIC RHEUMATIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
36. REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
